Table 3.
Screening efficacy for supplemental and primary US screening
| Author, year | Method | Cancer detected rate, 1/1000 | Recall rate, % | Biopsy rate, % | |||
|---|---|---|---|---|---|---|---|
| Number | 95% CI | Number | 95% CI | Number | 95% CI | ||
| Supplemental US screening studies | |||||||
| Tagliafico, 2016 [21] | Supplemental US | 23/3231 women | 7.1(4.6–10.8) | 88/3231 | 2.7(2.2–3.4) | 46/3231 | 1.4(1.1–1.9) |
| Kim, 2016 [22] | Supplemental US | 9/3171 women | 2.8(1.4–5.6) | 831/3171 | 26.2(24.7–27.8) | 147/3171 | 4.6(3.9–5.4) |
| Weigert, 2015 [26] | Supplemental US | 24/10282 women | 2.3(1.5–3.5) | 435/10282 | 4.2(3.9–4.6) | ||
| Hwang, 2015 [25] | Supplemental US | 8/1727 women | 4.6(2.2–9.5) | 100/1727 | 5.8(4.8–7.0) | 37/1727 | 2.1(1.5–3.0) |
| Moon, 2015 [24] | Supplemental US | 4/2005 women | 2.0(0.6–5.5) | 623/2005 | 31.1(29.1–33.2) | ||
| Parris, 2013 [28] | Supplemental US | 10/5519 women | 1.8(0.9–3.4) | 181/5519 | 3.3(2.8–3.8) | 181/5519 | 3.3(2.8–3.8) |
| Girardi, 2013 [27] | Supplemental US | 41/22131 women | 1.9(1.3–2.5) | 422/22131 | 1.9(1.7–2.1) | 422/22131 | 1.9(1.7–2.1) |
| Leong, 2012 [32] | Supplemental US | 2/141 women | 14.2(2.5–55.5) | 14/141 | 9.9(5.7–16.4) | 14/141 | 9.9(5.7–16.4) |
| Hooley, 2012 [31] | Supplemental US | 3/648 women | 4.6(1.2–14.7) | 153/648 | 23.6(20.4–27.1) | 46/648 | 7.1(5.3–9.4) |
| Corsetti, 2011 [33] | Supplemental US | 32/7224 examinations | 4.4(3.1–6.3) | 395/7224 | 5.5(5.0–6.0) | 395/7224 | 5.5(5.0–6.0) |
| Youk, 2011 [34] | Supplemental US | 10/446 examinations | 22.4(11.4–42.2) | 51/446 | 11.4(8.7–14.8) | 49/446 | 11.0(8.3–14.4) |
| Brancato, 2007 [36] | Supplemental US | 2/5227 women | 0.4(0.1–1.5) | 108/5227 | 2.1(1.7–2.5) | 58/5227 | 1.1(0.9–1.4) |
| Joint screening studies | |||||||
| Dong, 2017 [9] | Primary MAM | 84/31918 women | 2.6(2.1–3.3) | 688/31918 | 2.2(2.0–2.3) | ||
| Primary US | 61/31918 women | 1.9(1.5–2.5) | 450/31918 | 1.4(1.3–1.5) | |||
| Ohuchi, 2016 [10] | Primary MAM | 117/36049 women | 3.2(2.7–3.9) | 2417/36049 | 6.7(6.4–7.0) | ||
| Primary US | 143/36049 women | 4.0(3.4–4.7) | 2432/36049 | 6.7(6.5–7.0) | |||
| Berg, 2016 [11] | Primary MAM | 59/7473 examinations | 7.9(6.1–10.2) | 759/7473 | 10.2(9.5–10.9) | 162/7473 | 2.2(1.9–2.5) |
| Primary US | 58/7473 examinations | 7.8(6.0–10.1) | 1070/7473 | 14.3(13.5–15.1) | 499/7473 | 6.7(6.1–7.3) | |
| Shen, 2015 [23] | Primary MAM | 8/6930 examinations | 1.2(0.5–2.4) | 11/6930 | 0.2(0.1–0.3) | 7/6930 | 0.1(0.0–0.2) |
| Primary US | 14/6930 examinations | 2.0(1.2–3.5) | 20/6930 | 0.3(0.2–0.5) | 17/6930 | 0.2(0.1–0.4) | |
| Brem, 2015 [39] | Primary MAM | 82/15318 women | 5.4(4.3–6.7) | 2301/15318 | 15.0(14.5–15.6) | 586/15318 | 3.8(3.5–4.1) |
| Primary US | 95/15318 women | 6.2(5.0–7.6) | 2751/15318 | 18.0(17.4–18.6) | 552/15318 | 3.6(3.3–3.9) | |
| Huang, 2012 [30] | Primary MAM | 28/3028 women | 9.2(6.3–13.5) | 105/3028 | 3.5(2.9–4.2) | ||
| Primary US | 24/3028 women | 7.9(5.2–12.0) | 318/3028 | 10.5(9.4–11.7) | |||
| Kelly, 2010 [40] | Primary MAM | 23/4419 women | 5.2(3.4–7.9) | 59/4419 | 1.3(1.0–1.7) | 59/4419 | 1.3(1.0–1.7) |
| Primary US | 38/4419 women | 8.6(6.2–11.9) | 99/4419 | 2.2(1.8–2.7) | 99/4419 | 2.2(1.8–2.7) | |
| Wilczek, 2016 [38] | Primary MAM | 7/1668 women | 4.2(1.8–9.0) | 23/1668 | 1.4(0.9–2.1) | 11/1668 | 0.7(0.3–1.2) |
| Primary US | 11/1668 women | 6.6(3.5–12.2) | 38/1668 | 2.3(1.6–3.1) | 23/1668 | 1.4(0.9–2.1) | |
| Venturini, 2013 [29] | Primary MAM | 12/1666 women | 7.2(3.9–12.9) | 76/1666 | 4.6(3.6–5.7) | 14/1666 | 0.8(0.5–1.4) |
| Primary US | 2/835 women | 2.4(0.4–9.6) | 87/835 | 10.4(8.5–12.7) | 10/835 | 1.2(0.6–2.3) | |
| Weinstein, 2009 [35] | Primary MAM | 7/569 women | 12.3(5.4–26.3) | 42/569 | 6.9(5.1–9.3) | 20/569 | 3.3(2.1–5.1) |
| Primary US | 3/567 women | 5.3(1.4–16.7) | 39/567 | 6.9(5.0–9.4) | 20/567 | 3.5(2.2–5.5) | |
| Honjo, 2007 [37] | Primary MAM | 8/3543 women | 2.3(1.1–4.6) | 279/3543 | 7.9(7.0–8.8) | ||
| Primary US | 5/3543 women | 2.0(0.9–4.3) | 165/3543 | 4.7(4.0–5.4) | |||
CI Confidential interval;MAM Mammography; US Ultrasonography